Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial

The human monoclonal antibody opicinumab (BIIB033, anti-LINGO-1) has shown remyelinating activity in preclinical studies. We therefore assessed the safety and tolerability, and efficacy of opicinumab given soon after a first acute optic neuritis episode. This randomised, double-blind, placebo-contro...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lancet neurology Jg. 16; H. 3; S. 189 - 199
Hauptverfasser:	Cadavid, Diego, Balcer, Laura, Galetta, Steven, Aktas, Orhan, Ziemssen, Tjalf, Vanopdenbosch, Ludo, Frederiksen, Jette, Skeen, Mark, Jaffe, Glenn J, Butzkueven, Helmut, Ziemssen, Focke, Massacesi, Luca, Chai, Yi, Xu, Lei, Freeman, Stefanie
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England Elsevier Ltd 01.03.2017 Elsevier Limited
Schlagworte:	Acute Disease Adolescent Adult Antibodies, Monoclonal - therapeutic use Clinical trials Double-Blind Method Electroencephalography Evoked Potentials, Visual - drug effects Female Humans Immunoglobulins Immunologic Factors - therapeutic use International Cooperation Male Membrane Proteins - immunology Middle Aged Multiple sclerosis Nerve Tissue Proteins - immunology Neurology Optic Neuritis - drug therapy PubMed - statistics & numerical data Retrospective Studies Studies Treatment Outcome Young Adult
ISSN:	1474-4422, 1474-4465, 1474-4465
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!